Frontlight ResearchEarly access
Taking peoplePhase 3
A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult patients with invasive mold infections
Key facts
- Who runs it
- Basilea Pharmaceutica International AG Allschwil
- Where
- Austria, Belgium, France, Germany, Greece, Italy, Netherlands, and Spain38 sites in 8 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 94 people, planned
- Started
- 13 Feb 2026
- Expected to end
- 1 Feb 2028
- Type of study
- Interventional
- Record updated
- 14 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Diagnosis of proven or probable IMI defined in accordance with the Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the EORTC/MSGERC as adapted for this study and caused by Aspergillus spp. (in patients with limited treatment options), Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multi-drug resistant molds
- Patient’s condition allows for appropriate infection source control measures
Who cannot take part
- Current use of any prohibited concomitant medication(s)
- Current/previous administration of an investigational drug within 30 days
- Prior enrollment in this or any previous study of fosmanogepix
- Patients receiving hospice/comfort care only
- Refractory hematologic malignancy
- Other medical or psychiatric condition
- Moderate or severe hepatic impairment
- Known hypersensitivity to fosmanogepix, manogepix, or any of the excipients
- Chronic aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis
- Coronavirus disease 2019 (COVID-19) associated mucormycosis
- Invasive fungal disease caused by more than one fungal pathogen are not permitted in Cohort A but are permitted in Cohort B
- Patients with known human immunodeficiency virus infection
- Ongoing neurological disorders
- Patient who is pregnant or lactating
- Patients with a Karnofsky Performance Status < 20 at Screening
- Requirement, or anticipated requirement, for hemodialysis, peritoneal dialysis, or hemofiltration
This trial has no sites in United States.
It has sites in 8 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy of fosmanogepix for the treatment of adult patients with Invasive mold infections (IMIs) caused by Aspergillus spp. (in patients with limited treatment options), Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An interventional Phase 3, open-label, two-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds
- Record updated
- 14 September 2026